{
    "relation": [
        [
            "",
            "Maraviroc QD",
            "Maraviroc BID",
            "Placebo"
        ],
        [
            "Description",
            "Maraviroc 150 mg by mouth (PO) once daily (QD) in combination with optimized background therapy (OBT) (3 to 6 drugs based on treatment history and resistance testing). The 150 mg QD arm = placebo drug in the morning and active drug in the evening.",
            "Maraviroc 150 mg PO twice a day (BID) in combination with OBT (3 to 6 drugs based on treatment history and resistance testing). The 150 mg BID arm = active drug in the morning and evening.",
            "Placebo BID in combination with OBT (3 to 6 drugs based on treatment history and resistance testing). The placebo arm = placebo drug in the morning and evening."
        ]
    ],
    "pageTitle": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00098748?sect=Xh015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987155.85/warc/CC-MAIN-20150728002307-00280-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 861641263,
    "recordOffset": 861623908,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Optimized Background Therapy (OBT) Drug: maraviroc (UK-427,857) Interventions: HIV Infections Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: March 25, 2010 \u00a0",
    "textAfterTable": "Participant Flow for 3 periods Period 1: \u00a0 Assigned to Study Treatment \u00a0 \u00a0 Maraviroc QD \u00a0 \u00a0 Maraviroc BID \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 63 \u00a0 \u00a0 63 \u00a0 \u00a0 64 \u00a0 COMPLETED \u00a0 \u00a0 63 \u00a0 \u00a0 61 \u00a0 \u00a0 62 \u00a0 NOT COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 2 \u00a0 \u00a0 2 \u00a0 Randomized, but not treated \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Period 2: \u00a0 Received Study Treatment",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}